Evidence map›Paper›PMID 24465269›Full record

ArticleFuture virology2013

An Attenuated CMV Vaccine with a Deletion in Tegument Protein GP83 (pp65 Homolog) Protects against Placental Infection and Improves Pregnancy Outcome in a Guinea Pig Challenge Model.

Mark R Schleiss, Ryan Buus, K Yeon Choi, Alistair McGregor

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mark R SchleissUniversity of Minnesota Medical School, Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, 2001 6 Street SE, Minneapolis, MN 55455-3007.
Ryan BuusUniversity of Minnesota Medical School, Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, 2001 6 Street SE, Minneapolis, MN 55455-3007.
K Yeon ChoiUniversity of Minnesota Medical School, Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, 2001 6 Street SE, Minneapolis, MN 55455-3007.
Alistair McGregorUniversity of Minnesota Medical School, Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, 2001 6 Street SE, Minneapolis, MN 55455-3007.
University of Minnesota · US

Funding

Viral Immunomodulation and Rational CMV Vaccine DesignR01HD044864 · NICHD · UNIVERSITY OF MINNESOTA TWIN CITIES · PI GEBALLE, ADAM P., MCVOY, MICHAEL A · 2003 to 2015
$4.5M
VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMVR01HD038416 · NICHD · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SCHLEISS, MARK R. · 2000 to 2009
$2.2M
Placental trophoblast infection and TLR mediated response to congenital CMVR01AI100933 · NIAID · UNIVERSITY OF MINNESOTA · PI MCGREGOR, ALISTAIR · 2012 to 2015
$1.5M
Development of an effective DISC vaccine strategy against congenital CMVR01AI098984 · NIAID · UNIVERSITY OF MINNESOTA · PI MCGREGOR, ALISTAIR · 2012 to 2015
$1.4M
NIAID NIH HHS R01 AI098984NIAID NIH HHS R01 AI100933NICHD NIH HHS R01 HD038416NICHD NIH HHS R01 HD044864
6 · The paper itself

Abstract

aimsCongenital human cytomegalovirus (HCMV) infection can lead to long-term neurodevelopmental sequelae, including mental retardation and sensorineural hearing loss. Preconception vaccine strategies relevant to prevention of HCMV-mediated injury to the newborn can be studied in the guinea pig cytomegalovirus (GPCMV) model. The objectives of this study were: 1) to assess in guinea pigs the protective efficacy against congenital infection and disease of a recombinant live, attenuated vaccine with a targeted deletion of the GPCMV homolog of the HCMV pUL83 tegument protein, GP83; and, 2) to compare the extent of placental infection in vaccine and control groups, using an MATERIALS AND

methodsOutbred Hartley guinea pigs were vaccinated prior to pregnancy with a two-dose series of 5×10

resultsCompared to placebo-immunized controls, vaccination resulted in significantly reduced maternal DNAemia following SG challenge, and there was significantly decreased pup mortality in litters born to vaccinated dams (3/29; 10%), compared to control (35/50; 70%; p<0.001). By

conclusionsIn summary, preconception immunization with a GP83 deletion vaccine reduced maternal DNAemia and results in protection against congenital GPCMV-associated pup mortality compared to unvaccinated controls. Vaccination resulted in reduced placental infection, probably related to the reduction in maternal DNAemia. Although the pp65 homolog in GPCMV, GP83, is a known target of protective T cell immune responses, it is nevertheless dispensable for effective vaccination against maternal and fetal CMV disease in this model.

Indexed as

attenuated CMV vaccineCMV pp65CMV UL83Cytomegaloviruscytomegalovirus immune evasionCytomegalovirus vaccineGPCMV GP83Guinea pig challenge modelGuinea pig cytomegalovirusLiveVaccine efficacy

Identifiers

PMID24465269
PMCPMC3900008
OpenAlexW2118633863

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.